Hawkins (HWKN) Q2 Fiscal 2027 Earnings Preview: What Analysts Expect from the Specialty Chemicals Provider
Key Takeaways
- Hawkins, Inc. (HWKN) is scheduled to report its second quarter of fiscal 2027 results after the market close on October 26, 2026.
- Wall Street consensus points to earnings of roughly $1.22 per share, up from $1.08 a year earlier, on revenue near $302.7 million.
- Water Treatment remains the company's primary growth engine, supported by a steady cadence of acquisitions.
- Margins are a key focus after freight costs and last-in, first-out (LIFO) inventory accounting pressured gross profit in the prior quarter.
- Hawkins has a mixed beat record, exceeding the consensus earnings-per-share (EPS) estimate in only two of its last eight quarters.
- Investors will also watch the Food & Health Sciences segment, which has faced softness in food and nutrition end markets.
- For additional context on the ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover timely, data-driven trading ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Hawkins, Inc. (HWKN) is a specialty chemical and ingredients company headquartered in Roseville, Minnesota, operating across three segments: Water Treatment, Food & Health Sciences, and Industrial Solutions. Its fiscal year runs from April through March, meaning this report covers the three months ended late September 2026. The release matters because the company has leaned heavily on acquisitions to drive Water Treatment growth, and investors are watching whether that momentum can translate into consistent bottom-line expansion. The prior quarter saw record revenue alongside a decline in net income, underscoring the tension between top-line gains and margin pressure. This preview frames the key expectations heading into the print. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Hawkins to post second-quarter fiscal 2027 earnings of about $1.21 to $1.22 per diluted share, compared with $1.08 in the year-ago quarter, reflecting roughly 12% growth. The consensus revenue estimate sits near $302.7 million, an increase of approximately 8% from $280.43 million a year earlier. These figures follow a first quarter in which Hawkins reported $1.35 per share on revenue of $315.7 million, missing the consensus EPS estimate of about $1.41 even as revenue grew 8%.
Beyond the headline numbers, investors are likely to scrutinize segment-level performance, particularly Water Treatment revenue growth and whether Food & Health Sciences stabilizes after prior softness. Gross margin is another focal point: in the most recent quarter, higher freight costs and unfavorable LIFO (last-in, first-out) inventory accounting weighed on profitability. Given that Hawkins has beaten consensus EPS in only two of its last eight quarters, the market will be attentive to any divergence between reported figures and expectations.
Market Reaction and Investor Sentiment
Sentiment heading into the report is cautious. Hawkins shares have tended to pull back around recent earnings releases: the stock declined after its fiscal 2026 fourth-quarter, third-quarter, and second-quarter reports, and a post-earnings drift of roughly negative 3.2% was recorded following the July 2026 print. This pattern reflects investor concern that revenue growth, driven partly by acquisitions, is not yet translating into equivalent earnings growth.
Key risk factors to monitor include persistent freight cost pressure, integration expenses tied to recent deals, and any further weakness in food and nutrition end markets. A continued margin squeeze could dampen the stock's reaction even if top-line results meet expectations, while evidence of stabilizing margins and reaccelerating organic growth could temper recent skepticism. From what I see, the acquisition strategy in Water Treatment continues to stand out as the main driver worth tracking.
Forward Outlook and Key Factors to Monitor
Looking beyond the second-quarter report, investors will focus on whether Water Treatment's acquisition-driven growth continues to compound. Management has completed numerous acquisitions over recent years and signaled that future deals will remain concentrated in Water Treatment, where the company has built a full portfolio of chemicals, filtration products, and equipment. The pace and pricing of future acquisitions will shape both revenue growth and the balance of integration costs.
Margin recovery is another central theme. If freight costs normalize and LIFO inventory effects fade, gross profit could improve relative to recent quarters. At the same time, selling, general and administrative (SG&A) expenses have risen with acquired businesses, so operating leverage will depend on disciplined cost management.
On the balance sheet, management expects to reduce leverage to roughly 1x adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) by the end of fiscal 2027, while continuing to fund dividends and share repurchases. The company has paid dividends for 41 consecutive years. Finally, watch for commentary on the Food & Health Sciences segment, where a return to growth would provide a more balanced earnings contribution across the business. I’m watching this closely as the segment could add stability if it rebounds.
Using AI Tools for Deeper Analysis
In preparing for earnings seasons like this one, I find it helpful to run quick comparisons across peers with Tickeron’s AI Screener. The tool lets me apply filters for fundamentals, technical patterns, and recent performance so I can place HWKN in broader context without spending hours on manual screens. It has become a regular part of my workflow when evaluating specialty chemical names and similar growth stories.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HWKN's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HWKN turned positive on October 22, 2026. Looking at past instances where HWKN's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on HWKN as a result. In 69 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
HWKN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HWKN crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HWKN advanced for three days, in 223 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 191 of 297 cases where HWKN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HWKN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
HWKN broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. HWKN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.039) is normal, around the industry mean (2.372). P/E Ratio (34.103) is within average values for comparable stocks, (-17.543). Projected Growth (PEG Ratio) (2.531) is also within normal values, averaging (1.548). Dividend Yield (0.006) settles around the average of (0.040) among similar stocks. P/S Ratio (2.320) is also within normal values, averaging (48.960).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of specialty chemicals
Industry ChemicalsSpecialty